- Se ha administrado la primera dosis a los pacientes en el estudio clínico VIRAGE2 de Fase IIa, que

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analys

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosi

- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in

Trial is entitled "A Phase IIa, single-arm, single-center, open-label, proof-of-concept trial ev

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#

- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a

– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squ

- Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head and Neck Squam

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.05) per share which met the analyst c

– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treat

Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with

Theriva Biologics Inc. shares are trading higher Monday after announcing upcoming poster on VIRAGE p

TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1

- Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE

- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a

- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a

Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and an

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeuti

- Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in

- Avances en el desarrollo clínico del VCN-01 para el adenocarcinoma ductal pancreático y el retinob

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.12) per share which beat the analyst

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report)'s stock price traded down 4.9% on Wedn

Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Pha

Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Pha

- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination w

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report)'s share price was up 5.2% during mid-d

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report) shares were up 3.4% on Tuesday. The co